- Alpha Cognition (ACOG) is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program
- Administering ALPHA-1062 reduced the extent of the functional deficit and improved functional recovery of TBI animals compared to untreated animals
- The preclinical results, combined with clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI
- ALPHA-1062 demonstrated improved motor and sensory recovery
- Alpha Cognition Inc. is a clinical-stage, biopharmaceutical company
- Alpha Cognition Inc. (ACOG) is down 14.68 per cent, trading at C$0.93 per share at 3 pm EST
Alpha Cognition (ACOG) is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.
Michael McFadden, CEO of Alpha Cognition, sat down with Caroline Egan to discuss the results of the study and what lies ahead.
Administering ALPHA-1062 reduced the extent of the functional deficit and improved functional recovery of TBI animals compared to untreated animals suffering a TBI.
In four of five functional measures of recovery, the performance of the ALPHA-1062 treated group was indistinguishable from that of the uninjured cohort.
In a rodent model of TBI, ALPHA-1062 or vehicle was administered intranasally, with treatment initiated 2 hours after injury and continued twice daily for 35 days.
ALPHA-1062 demonstrated acute (functional) protection from injury, and significantly improved:
- motor and sensory functional recovery measured by motor skill assessment, sensory/motor skill assessment, and Modified Neurological Severity Score which comprises motor, sensory, balance and reflex assessment.
- cognitive functional recovery measured by tests which assess recognition memory, and spatial learning and memory.
The neuropathological assessment of the brains from each experimental group is ongoing and top-line results will be released in Q1, 2022.
TBI is a major cause of death and disability in the US and there is currently no proven effective pharmacological intervention for patients who sustain an acute closed head injury.
Alpha Cognition Inc. is a clinical-stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).
Alpha Cognition Inc. (ACOG) is down 14.68 per cent, trading at C$0.93 per share at 3 pm EST.